ArticleNature genetics2016
Co-occurrence of MYC amplification and TP53 mutations in human cancer.
Article in Nature genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Androgene Receptors Axis and DNA Damage Repair Genes From Plasma DNA (ctDNA) in Patients With Prostate Cancer
Breast Cancer Liquid Biopsy Stratification
Who cites it
30 citing papers in PubMed.
- EphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer.Cell death & disease · 2026Article
- Causality-aware graph neural networks for functional stratification and phenotype prediction at scale.NPJ systems biology and applications · 2025Article
- A tumorigenesis threshold for endogenous Myc revealed by dosage-compensation for Myc-haploinsufficiency in the absence of p53.bioRxiv : the preprint server for biology · 2025Article
- Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer.NPJ precision oncology · 2024Article
- Obesity-associated changes in molecular biology of primary breast cancer.Nature communications · 2023Article
- Modeling and predicting cancer clonal evolution with reinforcement learning.Genome research · 2023Article
- Cellular dynamics of distinct skeletal cells and the development of osteosarcoma.Frontiers in endocrinology · 2023Review
- Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.NPJ breast cancer · 2022Article
- A clinician's handbook for using ctDNA throughout the patient journey.Molecular cancer · 2022Review
- Metabolic Rewiring in Glioblastoma Cancer:Frontiers in oncology · 2022Review
- SCYN: single cell CNV profiling method using dynamic programming.BMC genomics · 2021Article
- Gene Transactivation and Transrepression in MYC-Driven Cancers.International journal of molecular sciences · 2021Review
- Identifying modules of cooperating cancer drivers.Molecular systems biology · 2021Article
- Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.Genome medicine · 2020Article
- Article
- Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.Genome medicine · 2020Article
- Rapid diagnosis and comprehensive bacteria profiling of sepsis based on cell-free DNA.Journal of translational medicine · 2020Article
- Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.Breast cancer research : BCR · 2019Article
- Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development.Genes & development · 2018Article
- Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.International journal of cancer · 2018Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26813759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.